Evidence for altered hepatic matrix degradation in genetic haemochromatosis

Gut

Volumn 42, Issue 5, 1998, Pages 715-720

  George, D K ^a   Ramm, G A ^a,c   Powell, L W ^a   Fletcher, L M ^a   Walker, N I ^b   Cowley, L L ^a   Crawford, D H G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Genetic haemochromatosis; Hepatic fibrosis; Hepatic stellate cell; Matrix metalloproteinase; Tissue inhibitor of metalloproteinase 1

Indexed keywords

COLLAGENASE; GELATINASE A; IRON; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADULT; ARTICLE; CONTROLLED STUDY; DEGRADATION; EXTRACELLULAR MATRIX; FEMALE; HEMOCHROMATOSIS; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PHLEBOTOMY; PRIORITY JOURNAL;

EID: 0031837715     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.42.5.715     Document Type: Article

References (36)

1. Powell LW, Bassett ML, Halliday JW. Hemochromatosis 1980 update. Gastroenterology 1980;78:374-81.
2. Neiderau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256-62.
3. Powell LW, Jazwinska EC, Halliday JW. Primary iron overload. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron metabolism in health and disease. London: Saunders, 1994:227-70.
4. Sallie R, Reed WD, Shilkin KB. Confirmation of the efficacy of the hepatic iron index in differentiating genetic haemochromatosis from alcoholic liver disease complicated by alcoholic haemosiderosis. Gut 1991;32:207-10.
5. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early haemochromatosis and determination of the critical level associated with fibrosis. Hepatology 1986;6:24-9.
6. Niederau C, Fischer R, Purschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
7. Cartwright GE, Edwards CQ, Kravitz K, et al. Hereditary hemochromatosis: phenotypic expression of the disease. N Engl J Med 1979;301:175-9.
8. Ahern M, Hall P, Halliday J, et al. Hepatic stellate cell nomenclature. Hepatology 1996;23:193.
9. Friedman SJ. Cellular basis of hepatic fibrosis. N Engl J Med 1993;164:1202-5.
10. Ramm GA, Li SCY, Li L, et al. Chronic iron overload causes in vivo activation of rat lipocytes. Am J Physiol 1995;268: G451-8.
11. Pietrangelo A, Gualdi R, Casalgrandi G, et al. Enhanced hepatic collagen type I mRNA expression into fat-storing cells in a rodent model of hemochromatosis. Hepatology 1994;19:714-21.
12. Ramm GA, Crawford DHG, Powell LW, et al. Hepatic stellate cell activation in genetic hemochromatosis: lobular distribution, effect of increasing hepatic iron and response to phlebotomy. J Hepatol 1997;26:584-92.
13. Arthur MJ. Degradation of matrix proteins in liver fibrosis Pathol Res Pract 1994;190:825-33.
14. Milani S, Herbst H, Schuppan D, et al. Differential expression of matrix metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 1994;144:528-37.
15. Arthur MJP, Stanley A, Iredale JP, et al. Secretion of 72kD type IV collagenase/gelatinase by cultured human lipocytes: analysis of gene expression, protein synthesis and proteinase activity. Biochem J 1992;287:701-7.
16. Vyas SK, Leyland H, Gentry J, et al. Rat hepatic lipocytes synthesize and secrete transin (stromelysin) in early primary culture. Gastroenterology 1995;109:889-98.
17. Iredale JP, Murphy G, Hembry RM, et al. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinase-1. J Clin Invest 1992;90:282-7.
18. Uneo T, Tamaki S, Sugawara H, et al. Significance of serum tissue inhibitor of metalloproteinase-1 in various liver diseases. J Hepatol 1996;24:177-84.
19. Murawaki Y, Ikuta Y, Koda M, et al. Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic liver disease: relationship to liver histology. Hepatology 1994;20:780-7.
20. Li J, Rosman AS, Leo MA, et a. Tissue inhibitor of metalloproteinase is increased in the serum of precirrhotic and cirrhotic alcoholic patients and can serve as a marker of fibrosis. Hepatology 1994;19:1418-23.
21. Murawaki Y, Yamamoto H, Kawasaki H, et al. Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma. Clin Chim Acta 1993;218:47-58.
22. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996;13:399-408.
23. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-4.
24. Kodama S, Iwata K, Iwata H, et al. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma. J Immunol Methods 1990;127:103-8.
25. Zhang J, Fujimoto N, Iwata K, et al. A one-step sandwich immunoassay for human matrix metalloproteinase 1 (interstitial collagenase) using monoclonal antibodies. Clin Chim Acta 1993;219:1-14.
26. Fujimoto N, Mouri N, Iwaka K, et al. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kD gelatinase type IV collagenase) using monoclonal antibodies. Clin Chim Acta 1993;221:91-101.
27. Obata K, Iwata K, Okada Y, et al. A one-step sandwich immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies. Clin Chim Acta 1992;211:59-72.
28. Ishimura E, Nishizawa Y, Shoji S, et al. Serum type III, IV collagens and TIMP in patients with type II diabetes mellitus. Life Sci 1996;58:1331-7.
29. Manicourt DH, Fujimoto N, Obata K, et al. Serum levels of collagenase, stromelysin-1, and TIMP-1. Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratin sulfate in patients with osteoarthritis. Arthritis Rheum 1994;37:1774-83.
30. Benyon CR, Iredale JP, Goddard S, et al. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996;110:821-31.
31. Murawaki Y, Ikuta Y, Idobe Y, et al. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol 1997;26:1213-19.
32. Nakatsukasa H, Ashida K, Higashi T, et al. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas. Hepatology 1996;24:82-8.
33. Terada T, Yasunori O, Nakanuma Y. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 1996;23:1341-4.
34. Roeb E, Graeve L, Mullberg J, et al. TIMP-1 protein expression is stimulated by IL-1β and IL-6 in primary rat hepatocytes. FEBS Lett 1994;349:45-9.
35. Arthur MJP, Iredale JP. Hepatic lipocytes, TIMP-1 and liver fibrosis. J R Coll Physicians Lond 1994;28:200-8.
36. Kasahara A, Hayashi N, Mochizuki K, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. J Hepatol 1997;26:574-3.